drugset
Drugs / recombinant SARS-CoV-2 vaccine (Sf9 Cell)
last change Nov 2021 re-read 3 minutes ago

recombinant SARS-CoV-2 vaccine (Sf9 Cell)

Vaccine

Developed for
COVID-19
Investigated by
Jiangsu Province Centers for Disease Control and Prevention · West China Hospital

Trials 1

today NCT04530656 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04530656 Aug → Oct 2020 COVID-19 Jiangsu Province Centers for Disease Control and Prevention Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as recombinant SARS-CoV-2 vaccine (Sf9 Cell) ClinicalTrials.gov intervention name — accepted as the source's own label NCT04530656 ↗
Modality Vaccine “Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)” NCT04530656 ↗
Route Intramuscular “each dose of either SARS-CoV-2 vaccine (Sf9 Cell) or placebo will be given intramuscularly (IM)” NCT04530656 ↗